You just read:

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

News provided by

Boehringer Ingelheim Pharmaceuticals

Nov 13, 2017, 20:30 ET